Discover other firms ranked in Life Sciences

2
Band 2
DLA Piper LLP
2
DLA Piper LLP
11 Years Ranked

View profile
Norton Rose Fulbright
2
Norton Rose Fulbright
11 Years Ranked

View profile
Ropes & Gray LLP
2
Ropes & Gray LLP
11 Years Ranked

View profile
3
Band 3
Covington & Burling LLP
3
Covington & Burling LLP
4 Years Ranked

View profile
Sidley Austin LLP
3
Sidley Austin LLP
10 Years Ranked

View profile

Chambers Review

Provided by Chambers
Life Sciences - Asia-Pacific Region
3
Band 3
What the team is known for

King & Wood Mallesons acts on a broad range of matters in the life sciences space in China and Australia, including IP, regulatory work, financing and dispute resolution. The firm is particularly well versed in anti-bribery investigations in the biopharma and medical devices sectors. It is also able to draw on the resources of a noted corporate practice for support on financing, restructuring, IPO and M&A transactions in this practice area. The firm maintains a large network of offices across the region, including in Hong Kong, Japan and Singapore.

Strengths

"They are a pleasure to work with; we are always briefed by them because everything is well prepared. They have a big team and they work well together."

Work highlights

King & Wood Mallesons acted for the University of Sydney on a claim by its employed researchers that it had failed to properly commercialise intellectual property which was comprised in a clinical trials database.

Notable practitioners

Matthew Swinn and Kim O'Connell are key contacts in Australia and Beijing-based Zhu Nongfan is the main contact in China.